Netarsudil, sold under the brand name Rhopressa, is a medication for the treatment of glaucoma. Reference standards of Netarsudil API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
(R)-4-(3-Amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate Dimethanesulfonate
Catalogue No.:PA 14 1201000
CAS :
Molecular Formula : C30H35N3O9S2
Molecular Weight : 645.74
4-(3-(1,3-Dioxoisoindolin-2-yl)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-Dimethylbenzoate
Catalogue No.:PA 14 1201001
Molecular Formula : C36H29N3O5
Molecular Weight : 583.64
(S)-4-(3-((Tert-butoxycarbonyl)amino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate
Catalogue No.:PA 14 1201002
Molecular Formula : C33H35N3O5
Molecular Weight : 553.66
Netarsudil Dimesylate
Catalogue No.:PA 14 1201003
Netarsudil
Catalogue No.:PA 14 1200000
Molecular Formula : C28H27N3O3
Molecular Weight : 453.54
(R)-3-Amino-2-(4-(hydroxymethyl)phenyl)-N-(isoquinolin-6-yl)propanamide
Catalogue No.:PA 14 1201004
Molecular Formula : C19H19N3O2
Molecular Weight : 321.38
(S)-3-Amino-2-(4-(hydroxymethyl)phenyl)-N-(isoquinolin-6-yl)propanamide
Catalogue No.:PA 14 1201005
(R)-4-(3-Amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate
Catalogue No.:PA 14 1201006
Netarsudil Amino Acid Impurity
Catalogue No.:PA 14 1201007
Molecular Formula : C19H21NO4
Molecular Weight : 327.38
tert-Butyl (S)-(2-(4-(hydroxymethyl)phenyl)-3-(isoquinolin-6-ylamino)-3-oxopropyl)carbamate
Catalogue No.:PA 14 1201008
Molecular Formula : C24H27N3O4
Molecular Weight : 421.5
(S)-3-((tert-Butoxycarbonyl)amino)-2-(4-(((tert-butyldimethylsilyl)oxy)methyl)phenyl)propanoic Acid
Catalogue No.:PA 14 1201009
Molecular Formula : C21H35NO5Si
Molecular Weight : 409.6
3-((tert-Butoxycarbonyl)amino)-2-(4-(((triisopropylsilyl)oxy)methyl)phenyl)propanoic Acid
Catalogue No.:PA 14 1201010
Molecular Formula : C24H41NO5Si
Molecular Weight : 451.68
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....
